A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Phase 3 Active not recruiting 12 enrolled Abeona Therapeutics, Inc

NaSingle-groupOpen-labelTreatment

Summary

To evaluate and further characterize the safety of EB-101 (LZRSE-Col7A1 gene-corrected keratinocyte sheets with type VII collagen \[C7\] expression) for the treatment of large, chronic DEB wounds in new and previously EB-101 treated patients 12 months and older.

Timeline

Start: 2023-04-02
Primary completion: 2025-09-30
Completion: 2025-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	prademagene zamikeracel	Cell therapy	—	Other

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Summary

Timeline

Drugs

Indications